Biomea Fusion Inc
NASDAQ:BMEA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9573
4.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biomea Fusion Inc
Other
Biomea Fusion Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$47m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$6.5B
|
CAGR 3-Years
-244%
|
CAGR 5-Years
-115%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$9.6B
|
CAGR 3-Years
-380%
|
CAGR 5-Years
-174%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$371.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$276.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
4%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.